This issue spotlights RAND's research on how providers can better meet the health care needs of veterans; life as a U.S. Army private; and Air Force efforts to improve leadership opportunities for women.
Jodi Liu, an associate policy researcher at RAND, studies how to deliver high-quality care and how to pay for it. She discusses her assessment of a single-payer health care proposal in New York State and the supply-and-demand challenges that might arise if an Alzheimer's treatment became available.
The health care systems in some European countries lack the capacity to rapidly move a disease-modifying treatment for Alzheimer's disease from approval into widespread clinical use, which could leave 1 million people without access to transformative care if such a breakthrough occurs.
A potential therapy for early-stage Alzheimer's patients might prevent or delay the progression to dementia. An assessment of how prepared six European nations are to deliver such a therapy indicates a pressing need to address health system constraints. One million patients could develop the disease while waiting for treatment.
A therapy for early-stage Alzheimer's disease could be available by 2020, but millions of European patients might have to wait a year or more for initial appointments in the multistep process if health care system capacity is not increased.
Among Americans aged 55-69, rates of cognitive limitation are many times higher for groups with lower socioeconomic status (SES) than those with higher SES, and recent trends show little indication that gaps are narrowing.
A nationally representative study of 16,000 U.S. seniors is the first to show that dementia and cognitive impairment are more common among rural seniors than their urban peers. However, rural investments in boosting high school graduation rates have narrowed the gap.
The U.S. health care system lacks the capacity to rapidly move a treatment for Alzheimer's disease from approval into wide clinical use, a shortcoming that could leave millions of people without access to transformative care if such a breakthrough occurs.
Drugs to halt the progression of Alzheimer's disease may be available by 2020, but millions of U.S. patients might have to wait more than 14 months for initial appointments in the multistep process unless health care system capacity is increased.
The U.S. health care system isn't ready to meet demand for a breakthrough Alzheimer's treatment. Results from clinical trials are producing guarded optimism that a breakthrough could arrive as early as 2020. If this happens, up to 2.1 million patients could develop Alzheimer's dementia by 2040 while on treatment and evaluation waiting lists.
In this nationally-representative sample of U.S. adults aged 51 and over, living in a neighborhood in the highest tertile of the percent of adults 65 and older was associated with significantly better cognitive function.
This publication highlights recent RAND social and economic policy research projects that have produced important new policies, framed issues in new ways, balanced multiple priorities and difficult trade-offs, and prompted meaningful change.
Research has proven that vaccines are extremely safe and effective. The public health implications of questioning this are serious. America should take every opportunity to protect kids by vaccinating them against every vaccine-preventable disease.
The total cost of caring for people in the United States with dementia in 2010 was estimated to be between $159 billion and $215 billion. As the nation's population ages, these costs will soar. Lawmakers could consider policy changes that support family caregivers and expand Medicaid eligibility.